Drug combo shows promise in early ovarian cancer trial

NCT ID NCT04502602

Ongoing Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least four months. Only 18 participants are enrolled, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib and neratinib (two cancer drugs taken as pills)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors or platinum-resistant ovarian cancer.
What could go wrong: This is a very early, small phase 1 trial with only 18 participants. The main goal is to find a safe dose, not to prove effectiveness. The combination may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm ovarian cancer ovarian carcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR OVARIAN CANCER

Contacts and locations

Locations

Virginia Commonwealth University

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.